Use of $^{18}$F-FDG PET/CT to Differentiate Ectopic Adrenocorticotropic Hormone-Secreting Lung Tumors From Tumor-Like Pulmonary Infections in Patients With Ectopic Cushing Syndrome

Guozhu Hou$^{1,2}$†, Yuanyuan Jiang$^{1,2}$†, Fang Li$^{1,2}$* and Xin Cheng$^{1,2}$*

$^1$ Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, $^2$ Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, China

*Correspondence: Xin Cheng chengx@pumch.cn Fang Li lifang@pumch.cn
†These authors have contributed equally to this work

Specialty section: This article was submitted to Cancer Imaging and Image-directed Interventions, a section of the journal Frontiers in Oncology

Background: Ectopic adrenocorticotropic hormone (ACTH)-secreting lung tumors represent the most common cause of ectopic Cushing syndrome (ECS). Pulmonary opportunistic infections are associated with ECS. The present study aimed to evaluate the usefulness of $^{18}$F-FDG PET/CT for differentiating ectopic ACTH-secreting lung tumors from tumor-like pulmonary infections in patients with ECS.

Methods: We retrospectively reviewed the imaging data of 24 patients with ECS who were suspected to have ACTH-secreting lung tumors and underwent $^{18}$F-FDG PET/CT between 2008 and 2019. Eleven patients with lung tumors and 4 with pulmonary infections also had additional somatostatin receptor imaging ($^{99m}$Tc-HYNIC-TOC SPECT/CT or $^{68}$Ga-DOTATATE PET/CT).

Results: In total, 18 patients had lung tumors and six had pulmonary infections. The primary source of ECS remained occult in the six patients with pulmonary infections. The maximum standardized uptake value ($SUV_{\text{max}}$) for pulmonary infections was significantly higher than that for tumors ($P = 0.008$). Receiver operating characteristic analysis revealed that a cut-off $SUV_{\text{max}}$ of 4.95 helped in differentiating ACTH-secreting lung tumors from infections with 75% sensitivity and 94.4% specificity. For the 11 patients with ACTH-lung tumors, somatostatin receptor imaging (SRI) was positive in 6; while for the 4 with pulmonary infections, SRI was positive in 2. The sensitivity and specificity of somatostatin receptor imaging (SRI) for detecting ACTH-secreting lung tumor was 54.5% and 50%.
INTRODUCTION

10%-15% of Cushing syndrome is caused by ectopic adrenocorticotropic hormone (ACTH)-secreting tumors. In such cases, resection of the tumors can have curative effects. The most common tumors associated with ECS are pulmonary carcinoids and small cell lung carcinoma (SCLC), followed by thymic carcinoids, pancreatic neuroendocrine tumors, medullary thyroid carcinoma, and pheochromocytoma (1). 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT; 18F-FDG PET/CT) has been shown to be an effective modality for localizing ectopic ACTH-secreting tumors causing ECS. Pulmonary carcinoids generally demonstrate low to moderate metabolic activity because of their low proliferation rate and slow growth. Meanwhile, ACTH-producing SCLC can show positive findings on 18F-FDG PET/CT, although the reported number of ECS-causing SCLCs detected by 18F-FDG PET/CT is quite small. This is probably because the patients are rapidly diagnosed by conventional cross-sectional imaging and do not undergo further 18F-FDG PET/CT (2).

ECS due to ectopic ACTH-secreting tumors is associated with markedly elevated ACTH levels. This results in high circulating glucocorticoid levels, which could affect cell-mediated immunity (3) and impair immune function by inhibiting the phagocytic function of alveolar macrophages and reducing neutrophil recruitment to the infected areas. This results in an increased incidence of opportunistic bacterial and fungal infections (4, 5). The four most common infections associated with ECS are cryptococcosis, aspergillosis, nocardiosis, and pneumocystosis (6), with the lung being the most frequently involved site. Pulmonary infections can exhibit varied radiographic findings and may appear as nodules or masses simulating lung tumors (7). Thus, it could be difficult for conventional anatomic imaging to differentiate tumor-like pulmonary infections from lung tumors. FDG is a nonspecific tracer that accumulates in areas of infection. Pulmonary cryptococcosis, aspergillosis, nocardiosis, and pneumocystosis have been reported to show high metabolic activity and mimic lung malignancies on 18F-FDG PET/CT (8–11). In the clinical setting of immunosuppression resulting from ECS, surgery for the removal of pulmonary infectious lesions can deteriorate the patient’s condition. Therefore, discrimination of infections and tumors is crucial for avoiding unnecessary surgical intervention. The primary goal of this retrospective study was to evaluate the usefulness of 18F-FDG PET/CT for differentiating ectopic ACTH-secreting lung tumors from tumor-like pulmonary infections in patients with ECS. In addition, as somatostatin receptor-based imaging (SRI) has been increasingly used for the detection of occult ECS tumors, we also reviewed the SRI imaging findings in 15 patients and investigated whether the SRI findings were able to differentiate the two conditions.

Conclusions: Our findings suggest that pulmonary infections exhibit significantly higher FDG uptake than ACTH-secreting lung tumors in 18F-FDG PET/CT. An SUV_{max} cut-off value of 4.95 may be useful for differentiating the two conditions. Our results also suggested that SRI may not be an effective tool for differentiating the two conditions given the relatively low specificity.

Keywords: ectopic Cushing syndrome, adrenocorticotropic hormone-secreting lung tumors, pulmonary infections, fluorodeoxyglucose, positron emission tomography/computed tomography

MATERIALS AND METHODS

Patients

We retrospectively reviewed 18F-FDG PET/CT scans obtained for localizing the source of ectopic ACTH secretion in all patients with ECS in our department between 2008 and 2019. The inclusion criteria were as follows: (a) confirmed diagnosis of ACTH-dependant Cushing syndrome; (b) negative finding on pituitary MRI; (c) lung nodules suspected on chest CT images. Exclusion criteria were as follows: (a) confirmed tumoral source other than in the lung (i.e. thymus, gastrointestinal tract and pancreatic neuroendocrine tumor), (b) unavailable histopathological result of suspected lung lesion. Eventually, 24 patients with suspicious ACTH-secreting lung tumors were included in the present study. The diagnosis of ECS was confirmed by clinical presentations combined with laboratory tests including low-dose dexamethasone suppression test (LDDST), high-dose dexamethasone suppression test (HDDST), CRH test, inferior petrosal sinus sampling (IPSS). The head MRI results of all patients suggested that the pituitary gland was normal. Pulmonary CT indicates pulmonary nodules, but the nature is unclear. Fifteen patients also underwent additional {99mTc-HYNIC SPECT/CT (n=6) or 68Ga-DOTATATE PET/CT (n=9). The reference standard was histopathological diagnosis obtained by either lung surgery or biopsy. There were 11 female and 13 male patients aged 9 to 72 years (mean age, 37.8 ± 17.1 years). This retrospective study of existing patient data and images was approved by the institutional review board of Peking Union Medical College Hospital. The requirement for informed consent was waived.

18F-FDG PET/CT Study

Following 8 h of fasting and confirming the blood glucose level to be less than 120 mg/dL, 18F-FDG (5.5 MBq/kg) was intravenously injected. An hour later, PET/CT images were acquired from the mid-thigh to the skull base (2 min/bed position) using a combined PET/CT Biograph (Siemens Co.). All scans were obtained in a three-dimensional model.
**99mTc-HYNIC-TOC Scintigraphy**

99mTc-HYNIC-TOC was synthesized and labeled as previously described (12). After intravenous administration of the tracer, whole-body planar images were acquired using a double-head gamma camera at 1 and 4 hours after injection. Some patients also underwent pulmonary SPECT/CT imaging when there is an increased uptake in the chest.

**68Ga-DOTA-TATE PET/CT Study**

The 68Ga-DOTATATE was produced following our previously published procedure (13). The study was carried out on a PET/CT scanner (Siemens Co.). Patients received an intravenous injection of 68Ga-DOTATATE (111-148 MBq). A low-dose whole-body CT scan was obtained at 40-60 min post-injection for anatomical localization and attenuation correction. PET scanning followed at 1.5 min/bed position with a 23-slice overlap. Images were reconstructed using an ordered subsets expectation-maximization algorithm and corrected for CT-based overlap. Images were reconstructed using an ordered subsets expectation-maximization algorithm and corrected for CT-based attenuation, dead time, random events, and scatter.

**Image Interpretation and Statistical Analysis**

The images were reviewed by two experienced nuclear medicine physicians, who visually inspected the images and performed semi-quantitative measurements based on the maximum standard uptake value (SUV$_{max}$), which is determined by selecting the point of maximum FDG uptake within the lesion. For 99mTc-HYNIC SPECT/CT and 68Ga-DOTATATE PET/CT, the images were interpreted as positive if the tracer uptake in the lesion was higher than surrounding background.

All data are expressed as mean ± standard deviation. Differences between groups were analyzed using the Student t-test, nonparametric analysis, and χ2 test. The cut-off SUV$_{max}$ for differentiating pulmonary infections from ACTH-secreting tumors was obtained via receiver operating characteristic (ROC) analysis with calculation of areas under the curve (AUCs) and sensitivity and specificity values. The correlation between the ACTH level and SUV$_{max}$ value was evaluated using the Pearson correlation coefficient. A P-value of <0.05 was considered statistically significant. All statistical analyses were performed using SPSS Statistics (version 21.0, IBM SPSS Inc., IBM, Chicago, IL, USA).

**RESULTS**

**Patients**

Among the 24 patients, 18 patients with 18 lesions were diagnosed with ectopic ACTH-secreting tumours (typical carcinoids, n =12; atypical carcinoids, n = 5; SCLC, n =1) while six patients with eight lesions were diagnosed with pulmonary infections (cryptococcosis, n = 3; aspergillosis, n = 4; pulmonary abscess, n = 1). Therefore, a total of 26 lesions were analyzed in this study. The patient characteristics are shown in Table 1. The clinical presentations are summarized in Table 2. After surgical resection of the lesions, all patients in the tumor group were relieved of all symptoms, with serum cortisol and ACTH levels returning to normal. On the other hand, the source of ectopic ACTH secretion remained occult in patients with pulmonary infections. One patient of the infection group died of cryptococcal meningitis after surgery resection of pulmonary nodule. Thirteen of the tumor group (4 typical carcinoids, 9 typical carcinoids) had follow up information. Two patients with atypical carcinoids developed recurrence, while no patient died during the follow-up period.

**18F-FDG PET/CT Results**

The mean SUV$_{max}$ for all 18 lesions in the patients with ectopic ACTH-secreting lung tumors was 2.1 ± 1.8 (range: 0.6–7.7), while that for the eight lesions in the patients with pulmonary infections was 5.9 ± 3.8 (range: 1.0–12.4). Thus, SUV$_{max}$ was significantly higher for infectious lesions than for tumors (P = 0.008; Figure 1). ROC curve analysis suggested that an SUV$_{max}$ of ≥4.95 was predictive of pulmonary infection with 75% sensitivity and 94.4% specificity; AUC was 0.833 (standard error, 0.093; P = 0.008; 95% confidence interval, 0.651–1.000; Figure 2). The mean diameters of the ectopic ACTH-secreting lung tumors and pulmonary infectious lesions were 13.8 ± 7.9 (range: 5–37) and 20.9 ± 11.0 (range: 7–35) mm, respectively, with no significant between-group difference (P = 0.126; Table 3). Figures 3–7 present representative cases of cryptococcosis (two lesions; SUV$_{max}$ values 5.7 and 12.4), aspergillosis (SUV$_{max}$ 1.0), a typical carcinoid (SUV$_{max}$ 2.7), an atypical carcinoid (SUV$_{max}$ 1.1), and small cell lung cancer (SUV$_{max}$ 7.7), respectively. The ACTH level was not significantly correlated with the SUV$_{max}$ value for ACTH-secreting lung tumors (P=0.816).

**SRI Results**

Four patients of the infection group had SRI, of which 3 had 99mTc-HYNIC SPECT/CT and 1 had 68Ga-DOTATATE PET/CT. Two of the 4 patients had positive imaging results. Eleven patients of the tumor group had SRI, of which 3 had 99mTc-HYNIC SPECT/CT and 8 had 68Ga-DOTATATE PET/CT. Six of the 11 patients had positive imaging results. Therefore, the sensitivity and specificity of SRI was 54.5% and 50%, respectively.

**DISCUSSION**

Ectopic ACTH-producing tumors account for 15%–20% of cases of ACTH-dependent Cushing syndrome. Lung carcinoids and SCLC represent the most common tumors associated with ECS, and the resection of the responsible tumors can have curative effects (14). There is no consensus regarding the usefulness of 18F-FDG PET/CT for localizing the source of ectopic ACTH secretion, even though it is the most commonly used molecular imaging method in clinical practice. A nodule or mass-like lesion in the lung that demonstrates abnormal activity on 18F-FDG PET/CT tends to be interpreted as an ACTH-secreting tumor and might be surgically resected. However, in clinical practice, the resected pulmonary ‘tumor’ occasionally turns out to be an infectious lesion most often caused by fungus. In such cases, surgery is unnecessary and may deteriorate the patient’s condition. The present study included 18 patients with ectopic ACTH secretion.
ACTH-secreting lung tumors and six patients with pulmonary infections. To the best of our knowledge, this is the first study to describe and compare the features of ACTH-secreting lung tumors and pulmonary infectious pseudotumors using 18F-FDG PET/CT. This discrimination is important because the two conditions require different treatment plans.

We found that a cut-off SUV\textsubscript{max} of 4.95 maximized the sensitivity and specificity for the differentiation of pulmonary infections from ACTH-secreting tumors. Specifically, the findings indicated that a pulmonary nodule or mass-like lesion with a SUV\textsubscript{max} of ≥4.95 was more likely to be an infectious lesion. Our study included only one SCLC, and it was the only lesion with a SUV\textsubscript{max} of >4.95 in the tumor group (SUV\textsubscript{max}, 7.7). SCLCs generally exhibit high FDG uptake on PET/CT because of their aggressiveness and high metabolic activity (15). The SCLC was underrepresented in our series, probably because most SCLCs are rapidly diagnosed by conventional cross-sectional imaging and do not require 18F-FDG PET/CT or other nuclear imaging modalities for localization (2).

The present study showed significantly higher FDG accumulation in infectious lesions than in pulmonary carcinoids. The reason for the low FDG uptake of pulmonary carcinoids is that

| TABLE 1 | Clinical features of ectopic Cushing syndrome patients, including histopathological characteristics, metastases, size, and SUV\textsubscript{max} of lesions. |
|---------|---------------------------------|---------------------------------|---------------------------------|-----------------|-----------------|-----------------|
| Patient | Sex/age | ACTH (pg/ml)* | Histopathological characteristics | Metastases | Diameter (mm) | SUV \textsubscript{max} (18F-FDG PET/CT) | SRI result |
|---------|---------|----------------|---------------------------------|------------|----------------|----------------------------|------------|
| Infectious lesions | | | | | | | |
| 1 | F/60 | 326 | cryptococcus | N/A | 7 | 1.2 | Negative |
| 2 | F/41 | 59.1 | Abscess | N/A | 32 | 6.2 | Positive |
| 3 | F/34 | 49.5 | cryptococcus | N/A | 14 | 5.7 | Positive |
| 4 | F/34 | 49.5 | cryptococcus | N/A | 35 | 12.4 | NA |
| 5 | M/53 | 1041 | Aspergillus | N/A | 32 | 9.7 | NA |
| 6 | M/53 | 1041 | Aspergillus | N/A | 12 | 5.2 | NA |
| ACTH-secreting tumors | | | | | | | |
| 7 | M/28 | 191 | TC (ACTH, +; Ki-67, 1%; TTF-1, +) | - | 10 | 0.6 | Positive |
| 8 | M/29 | 116 | TC (ACTH, +; Ki-67, 3%) | - | 12 | 4.7 | NA |
| 9 | F/9 | 115 | AC (ACTH, +; Number of mitosis, 1/10 HPF; Ki-67, 15%; TTF-1, -) | - | 14 | 1.4 | Positive |
| 10 | M/24 | 222 | TC (ACTH, +; Ki-67, 3%; TTF-1, +) | + | 17 | 2.7 | Positive |
| 11 | F/48 | 153 | TC (ACTH, +; Ki-67, 2%) | - | 5 | 0.8 | NA |
| 12 | F/27 | 111 | TC (ACTH, +; Ki-67, 3%) | - | 8 | 0.9 | Negative |
| 13 | M/22 | 140 | AC (ACTH, +; Number of mitosis, 3/10 HPF; Ki-67, 6%) | + | 6 | 0.9 | Negative |
| 14 | M/13 | 107 | TC (ACTH, +; Ki-67, 1%; TTF-1, -) | + | 10 | 1.1 | Negative |
| 15 | M/45 | 68.3 | AC (ACTH, +; Number of mitosis, 8/10 HPF; Ki-67, 10%; TTF-1, +) | + | 10 | 1.9 | Positive |
| 16 | M/30 | 100 | TC (ACTH, +; Number of mitosis, 1/10 HPF; Ki-67, 10%; TTF-1, +) | - | 11 | 0.6 | Negative |
| 17 | F/72 | 129 | TC (ACTH, +; Ki-67, 2%; TTF-1, +) | - | 15 | 2.8 | NA |
| 18 | F/44 | 874 | TC (ACTH, +; Ki-67, 1%) | + | 9 | 0.7 | NA |
| 19 | F/45 | 60.6 | TC (ACTH, +; Ki-67, 2%; TTF-1, +) | + | 16 | 3.8 | NA |
| 20 | F/52 | 572 | TC (ACTH, +; Ki-67, 2%; TTF-1, +) | + | 14 | 3.4 | Negative |
| 21 | M/16 | 130 | AC (ACTH, +; Ki-67, 5%; TTF-1, +) | - | 19 | 1.1 | Positive |
| 22 | M/12 | 865 | AC (ACTH, +; Ki-67, 2%) | + | 28 | 3.0 | Positive |
| 23 | M/62 | 278 | TC (ACTH, +; Ki-67, 1%; TTF-1, +) | - | 7 | 0.6 | NA |
| 24 | M/57 | 261 | SCLC (ACTH, +; Ki-67, 25%) | + | 37 | 7.7 | NA |

SUV\textsubscript{max}, maximum standardized uptake value; N/A, not applicable; AC, atypical carcinoid; TC, typical carcinoid; F, female; M, male; SCLC, small cell lung cancer; SRI, somatostatin receptor imaging. *Reference range for ACTH: 0-46 pg/ml.

| TABLE 2 | Clinical presentations of patients. |
|---------|---------------------------------|
| Clinical presentations | Patients, n (%) |
| Round face | 21, (87.5%) |
| Dorsal fat pad | 19, (79.1%) |
| Skin alterations | 18, (75%) |
| Weight gain | 16, (66.7%) |
| Hypertension | 16, (66.7%) |
| Hirsutism | 6, (25%) |
| Menstrual irregularities | 3, (12.5%) |
| Hair loss | 1, (4.1%) |

FIGURE 1 | SUV\textsubscript{max} was significantly higher for infectious lesions than for ACTH-secreting tumors (P = 0.008).
most of the lesions (17/18) are well-differentiated neuroendocrine neoplasms (16). As mentioned above, patients with poorly differentiated neuroendocrine neoplasms such as SCLC are rarely examined by FDG PET/CT, which is why we have fewer patients in this group. Among the eight infectious lesions, only two showed low FDG uptake with a SUVmax of <4.95. One of the lesions (Patient 1, SUVmax 1.2) was due to cryptococcosis, and it was the smallest lesion among the infectious lesions (0.7 cm in diameter). The other infectious lesion with low FDG uptake was an aspergilloma (Patient 4, SUVmax 1.0). Pulmonary aspergillosis can be divided into four subtypes on the basis of clinical and radiological findings: aspergilloma, allergic bronchopulmonary aspergillosis, chronic necrotizing aspergillosis, and invasive pulmonary aspergillosis (IPA) (17). The first three subtypes are also considered to be non-invasive pulmonary aspergillosis (NIPA) (17). Kim et al. evaluated the FDG PET/CT scans of 24 patients with pulmonary aspergillosis (8 IPA and 16 NIPA) and concluded that an isometabolic pattern on FDG PET/CT most likely represented NIPA (18). NIPA is a chronic infection with low virulence and a mild inflammatory reaction, which might attribute to the low metabolic activity on 18F-FDG PET/CT.

Somatostatin receptor-based imaging techniques including octreoscan-SPECT/CT and 68Ga-DOTATATE PET/CT have also been shown to be helpful in localizing the source of ECS (19). 68Ga-SSTR PET/CT demonstrated high sensitivity in detecting ECS tumors. Two recent systematic reviews reported a sensitivity of 76.1% and 81.8% for 68Ga-SSTR PET/CT (2, 20). However, in this study, the sensitivity (54.5%) of SRI (68Ga-DOTATATE PET/CT and 99mTc-HYNIC-SPECT/CT) was lower than previously reported. One reason may be publication bias as negative results tend to be not reported. Another reason might be

**TABLE 3 | Imaging characteristics of ectopic Cushing syndrome patients.**

| ACTH-secreting tumors (n = 18) | Infectious lesions (n = 8) | P value |
|--------------------------------|--------------------------|--------|
| **Diameter (mm)**              |                          |        |
| 13.8 ± 7.9 (5-37)              | 20.9 ± 11.0 (7-35)       | 0.126  |
| **SUVmax**                     |                          |        |
| 2.1 ± 1.8 (0.6-7.7)            | 5.9 ± 3.8 (1.0-12.4)     | 0.008  |

SUVmax, maximum standardized uptake value.

**FIGURE 3 |** 18F-FDG PET/CT and 99mTc-HYNIC-TOC SPECT/CT findings in a representative case of cryptococcosis (Patient, 3). A 34-year-old woman with ectopic Cushing syndrome underwent 18F-FDG PET/CT and 99mTc-HYNIC-TOC SPECT/CT for the detection of ACTH-secreting tumor. 18F-FDG PET/CT showed a mass in the right lung (A-D; red arrows, 3.5cm, SUVmax, 12.4). A hypermetabolic nodule near the right hilum was also noted (A; green arrow, 1.4cm, SUVmax, 5.7). The mass demonstrated positive uptake on 99mTc-HYNIC-TOC SPECT/CT (E-H; blue arrows), and the nodule showed slightly increased uptake. The two lesions were then surgically removed and histopathological results confirmed pulmonary cryptococcosis. Three weeks after surgery, the patient developed severe headache and fever symptoms. Cryptococcus cerebrospinal culture was positive, suggesting cryptococcal meningitis. The patient responded poorly to the antibiotic therapy and died of cerebral hernia.
that our study only included patients with lung tumors. Better performance of $^{68}$Ga-SSTR PET/CT is reported in ACTH-secreting gastroenteropancreatic (GEP) neuroendocrine tumor (NET) (2, 21). Goroshi et al. reported similar $^{68}$Ga-DOTANOC sensitivity of 60% (6/10) to ours for lung lesions while 100% (3/3) for GEP-NETs (21). Our results also showed that the specificity of SRI (50%) is quite low as two cases of the infection group showed positive finding on $^{99m}$Tc-HYNIC-TOC SPECT/CT, which were misdiagnosed as the culprit tumors of ECS and were then surgically resected. Inflammatory disease demonstrating increased tracer uptake on SRI is not uncommon in the literature because somatostatin receptor is known to be expressed on activated macrophages in inflammatory process (22, 23). These findings suggested that SRI may not effectively discriminate tumor-like infectious lesions from ACTH-secreting lung tumors.

The main limitations of this study were the small sample size, which does not allow for powerful statistical analysis, and retrospective design. In addition, the number of patients who had follow-up data is small, thus we did not perform statistical analysis on survival. The prognostic value of $^{18}$F-FDG PET/CT needs to be investigated in future study. Finally, as 6 of the 15 patients who had SRI had $^{99m}$Tc-HYNIC-TOC SPECT/CT, we could not perform semi-quantitative analysis. Future studies are required to investigate whether there is a difference in intensity of $^{68}$Ga-DOTATATE uptake between lung infectious lesions and tumors.

In conclusion, although pulmonary infectious lesions associated with ECS and ACTH-secreting lung tumors might exhibit similar morphological features, the former may show higher FDG activity on $^{18}$F-FDG PET/CT.
FIGURE 5 | $^{18}$F-FDG and $^{68}$Ga-DOTATATE PET/CT findings in a representative case of typical carcinoid (Patient, 10). A 24-year-old man with ectopic Cushing syndrome underwent $^{18}$F-FDG and $^{68}$Ga-DOTATATE PET/CT for detecting the source tumor of ACTH secretion. $^{18}$F-FDG PET/CT showed a nodule with mild activity (A–D; red arrows; SUVmax, 2.7) in the left lung. $^{68}$Ga-DOTATATE PET/CT also demonstrated slightly increased uptake in the nodule (E–H; blue arrows; SUVmax, 2.0), indicating somatostatin receptor expression. The nodule was then surgically removed and postoperative histopathology confirmed typical carcinoid with ACTH positivity in immunohistochemistry.

FIGURE 6 | $^{18}$F-FDG PET/CT findings in a representative case of atypical carcinoid (Patient, 21). A 16-year-old man was diagnosed with ectopic Cushing syndrome. The patient underwent $^{18}$F-FDG PET/CT to localize the source of ACTH secretion. PET/CT images revealed a nodule with mild FDG activity (A–D; arrows; SUVmax, 1.1) in the right lung. The lesion was surgically removed, and histopathological analysis confirmed the diagnosis of atypical carcinoid with ACTH positivity in immunohistochemistry.
An SUVmax of 4.95 may help differentiate the two conditions. While our results suggested that SRI may not be an effective tool for differentiating the two conditions given the relatively low specificity.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

Written informed consent was not obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

REFERENCES

1. Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK. Cushing’s Syndrome Due to Ectopic Corticotropin Secretion: Twenty Years’ Experience at the National Institutes of Health. J Clin Endocrinol Metab (2005) 90 (8):4953–62. doi: 10.1210/jc.2004-2527
2. Isidori AM, Sbardella E, Zatelli MC, Boscetti M, Vitale G, Colao A, et al. Conventional and Nuclear Medicine Imaging in Ectopic Cushing’s Syndrome; a Systematic Review. J Clin Endocrinol Metab (2015) 100(9):3231–44. doi: 10.1210/jc.2015-1589
3. Auphan N, DiDonato JA, Rosette C, Helmbrecht A, Karin M. Immunosuppression by Glucocorticoids: Inhibition of NF-Kappa B Activity Through Induction of I kappa B Synthesis. Science (1995) 270(5234):286–90. doi: 10.1126/science.270.5234.286
4. Walsh TJ, Roiildes E, Cortez K, Kottvilil S, Bailey J, Lyman CA. Control, Immunoregulation, and Expression of Innate Pulmonary Host Defenses

AUTHOR CONTRIBUTIONS

GH, YJ, FL, and XC contributed to the design and implementation of the research, to the analysis of the results, and to the writing of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work is supported by National Natural Science Foundation of China (no.81501513), Chinese Academy of Medical Sciences Initiative for Innovative Medicine (CAMS-I2M) 2017-I2M-1-001, and the National Key Research and Development Program of China (No. 2016YFC0901500).
11. Kono M, Yamashita H, Kubota K, Kano T, Mimori A. FDG PET Imaging in Neuroendocrine Tumors Depends on the Neutrophil Depletion Strategy. *Infect Immun* (2005) 73(1):114–25. doi: 10.1128/iai.73.1.114-125.2005

12. Vanfleteren M, Dingemans AC, Surmont VF, Vermaelen KY, Postma AA, Oude Lashof AML, et al. Invasive Aspergillosis Mimicking Metastatic Lung Cancer. *Front Oncol* (2018) 8:188. doi: 10.3389/fonc.2018.00188

13. Zhu W, Cheng Y, Wang X, Yao S, Bai C, Zhao H, et al. A Systematic Literature Review and Single-Center Clinical Experience. *J Nucl Med* (2015) 56(4):515–22. doi: 10.2967/jnumed.115.143881

14. Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ. 99mTc-HYNIC-Tyr3-Octreotide for Imaging Somatostatin-Receptor-Positive Tumors: Preclinical Evaluation and Comparison With 111In-Octreotide. *J Nucl Med* (2000) 41(6):1114–9.

15. Sharma P, Mukherjee A, Karunathithi S, Bal C, Kumar R. Potential Role of 18F-FDG PET/CT in Patients With Fungal Infections. *AJR Am J Roentgenol* (2014) 203(1):180–9. doi: 10.2214/ajr.13.11712

16. Kalemkerian GP. Small Cell Lung Cancer. *Semin Respir Crit Care Med* (2009) 30(4):378–9. doi: 10.1055/s-0036-1592116

17. Zhu W, Cheng Y, Wang X, Yao S, Bai C, Zhao H, et al. Head-to-Head Comparison of (68)Ga-DOTA-JR11 and (68)Ga-DOTATATE PET/CT in Patients With Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study. *J Nucl Med* (2020) 61(6):897. doi: 10.2967/jnumed.119.235093

18. La Rosa S, Volante M, Uccella S, Maragliano R, Rapa I, Rotolo N, et al. ACTH-Producing Tumorlets and Carcinoids of the Lung: Clinico-Pathologic Study of 63 Cases and Review of the Literature. *Virchows Arch* (2019) 475(5):587–97. doi: 10.1007/s00428-019-02612-x

19. Varlamov E, Hinojosa-Amaya JM, Stack M, Fleseriu M. Diagnostic Utility of Gallium-68-Somatostatin Receptor PET/CT in Ectopic ACTH-Producing Tumors: A Systematic Literature Review and Single-Center Clinical Experience. *Pituitary* (2019) 22(5):445–55. doi: 10.1007/s11122-019-00972-w

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Hou, Jiang, Li and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.